ArticleScientific reports2026
DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Kidney fibrosis is a central pathological feature driving progressive functional decline in chronic kidney disease (CKD); however, the molecular and epigenetic mechanisms linking kidney fibrosis to aging remain incompletely understood. In this study, we employed a natural aging mouse model and integrated transcriptomic and DNA methylation analyses to delineate age-associated kidney degenerative features and to identify key genes involved in this process. Our results showed that aging kidneys exhibited pronounced interstitial fibrosis and tubular atrophy, accompanied by increased expression of senescence markers, senescence-associated secretory phenotype (SASP) factors, and kidney injury molecule-1 (KIM-1), indicating persistent kidney injury during aging. Reduced representation bisulfite sequencing (RRBS) revealed a global, age-dependent increase in DNA methylation levels. Integrative methylome-transcriptome analyses identified fibroblast growth factor receptor 2 (FGFR2) as a prominent target of age-associated hypermethylation. Multilevel validation using RT-qPCR, Western blotting, immunofluorescence co-localization, and pyrosequencing consistently confirmed that FGFR2 expression was significantly reduced in aging kidney tissue, particularly in kidney tubular regions. Functional studies demonstrated that pharmacological inhibition of FGFR2 in vitro accelerated cellular senescence and upregulated fibrosis-related markers, supporting a causal role for FGFR2 loss in promoting kidney aging. Furthermore, reduced FGFR2 expression was accompanied by decreased co-localization with fibroblast growth factor 23 (FGF23) in aging kidneys, suggesting potential impairment of the FGF23/FGFR2 signaling axis. Collectively, these findings suggest that epigenetic silencing of FGFR2 contributes to kidney senescence and fibrotic remodeling during kidney aging and highlight FGFR2 as a potential therapeutic target for mitigating age-related kidney decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.